Equities analysts predict that Myokardia Inc (NASDAQ:MYOK) will report earnings per share of ($0.40) for the current quarter, according to Zacks. Two analysts have made estimates for Myokardia’s earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.46). Myokardia posted earnings of $0.44 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 190.9%. The business is expected to issue its next earnings results on Monday, March 12th.
According to Zacks, analysts expect that Myokardia will report full-year earnings of ($1.62) per share for the current financial year, with EPS estimates ranging from ($1.73) to ($1.49). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.80) per share, with EPS estimates ranging from ($2.22) to ($1.01). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Myokardia.
Myokardia (NASDAQ:MYOK) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.42) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.42). The company had revenue of $5.63 million for the quarter, compared to analyst estimates of $6.10 million. Myokardia had a negative return on equity of 14.92% and a negative net margin of 53.49%. The firm’s revenue for the quarter was up 58.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.35) EPS.
Several research firms have recently commented on MYOK. BidaskClub lowered Myokardia from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. Zacks Investment Research upgraded Myokardia from a “sell” rating to a “hold” rating in a report on Tuesday, October 17th. ValuEngine lowered Myokardia from a “hold” rating to a “sell” rating in a report on Friday, December 1st. JPMorgan Chase & Co. began coverage on Myokardia in a report on Tuesday, December 12th. They set an “overweight” rating and a $54.00 price target on the stock. Finally, Credit Suisse Group reiterated an “outperform” rating and set a $60.00 price target on shares of Myokardia in a report on Thursday. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $55.67.
Myokardia (NASDAQ:MYOK) traded up $1.05 during midday trading on Friday, hitting $53.95. The stock had a trading volume of 640,192 shares, compared to its average volume of 506,273. Myokardia has a fifty-two week low of $10.55 and a fifty-two week high of $54.85. The stock has a market cap of $1,930.00 and a price-to-earnings ratio of -72.91.
In related news, CEO Anastasios Gianakakos sold 4,300 shares of the business’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $40.23, for a total value of $172,989.00. Following the sale, the chief executive officer now directly owns 513,417 shares in the company, valued at approximately $20,654,765.91. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Joseph Lambing sold 5,000 shares of the business’s stock in a transaction dated Friday, January 12th. The shares were sold at an average price of $50.00, for a total transaction of $250,000.00. Following the completion of the sale, the insider now owns 95,846 shares in the company, valued at $4,792,300. The disclosure for this sale can be found here. In the last quarter, insiders have sold 841,626 shares of company stock worth $35,396,501. Insiders own 33.40% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN raised its holdings in Myokardia by 2.5% in the 2nd quarter. Wells Fargo & Company MN now owns 18,539 shares of the biotechnology company’s stock valued at $243,000 after buying an additional 455 shares during the period. American International Group Inc. raised its holdings in Myokardia by 18.8% in the 3rd quarter. American International Group Inc. now owns 12,735 shares of the biotechnology company’s stock valued at $546,000 after buying an additional 2,018 shares during the period. Rhumbline Advisers raised its holdings in Myokardia by 12.4% in the 3rd quarter. Rhumbline Advisers now owns 20,788 shares of the biotechnology company’s stock valued at $891,000 after buying an additional 2,299 shares during the period. Nationwide Fund Advisors raised its holdings in Myokardia by 36.3% in the 2nd quarter. Nationwide Fund Advisors now owns 9,729 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 2,591 shares during the period. Finally, Hershey Trust Co. raised its holdings in Myokardia by 26.0% in the 3rd quarter. Hershey Trust Co. now owns 20,064 shares of the biotechnology company’s stock valued at $860,000 after buying an additional 4,145 shares during the period. Hedge funds and other institutional investors own 63.61% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/13/zacks-analysts-expect-myokardia-inc-myok-will-announce-earnings-of-0-40-per-share.html.
Myokardia Company Profile
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Get a free copy of the Zacks research report on Myokardia (MYOK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.